Compounds

Details Compounds Compounds

2000-02-09

2002-03-19

Huff, Sheela (Department: 1642)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C536S023100

Reexamination Certificate

active

06359116

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.
BACKGROUND OF THE INVENTION
The drug discovery process is currently undergoing a fundamental revolution as it embraces ‘functional genomics’, that is, high throughput genome- or gene-based biology. This approach is rapidly superceding earlier approaches based on ‘positional cloning’. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
Functional genomics relies heavily on the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.
SUMMARY OF THE INVENTION
The present invention relates to HE8AN36, in particular HE8AN36 polypeptides and HE8AN36 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of chronic and acute inflammation, arthritis, autoimmune diseases, diabetes, transplant rejection, graft vs. host disease, reproductive disorders, cancer, obesity, atheroschlerosis, gyrate atrophy and other visual disorders, hereinafter referred to as “the Diseases”, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with HE8AN36 imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate HE8AN36 activity or levels.


REFERENCES:
patent: 5389517 (1995-02-01), Wotiz et al.
patent: 5958710 (1999-09-01), Kuiper et al.
patent: 0752477 (1997-01-01), None
patent: WO 99/03168 (1988-05-01), None
patent: WO 97/09348 (1997-03-01), None
patent: WO 99/10367 (1999-04-01), None
Skolnick et al, TIBTECH vol. 18 p. 34 (Jan. 2000).*
GenBank Accession No. Z42949 (1994).
Chen et al., “Identificatin of two hERR2-related novel nuclear receptors utilizing bioformalities and Inverse PCR”, Gene vol. 228 pp. 101-109 (1999).
Database PIR 58, Accession No. B29345 (1988).
Database PIR 58, Accession No. S58087 (1995).
Database GenBank, subsection EST, Accession No. W 26275 (1996).
Gigurere V. et al., “Identification of a new class of steroid hormone receptors, ”Nature, vol. 331, p. 91 (1988).
GenBank Accession No. Y00290 (1990).
GenBank Accession No. X51416 (1990).
GenBank Accession No. X51417 (1990).

Affiliated with

Also associated with

Rating

Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2827254